Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7296682 + Atezolizumab in Advanced Solid Tumors
NCT04642365Phase 1Terminated
- Sponsor
- Roche
- Start
- Jan 2021
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 1, open-label trial of vopikitug in solid tumor (2 arms), sponsored by Roche. Primary endpoints: Number of Participants With Adverse Events at 9.3 months, Number of Participants With Dose-Limiting Toxicities and 1 more. Started Jan 2021; status: terminated.
02
Drugs
vopikitug
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04642365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04642365.